Traditional endpoints used in clinical trials are commonly episodic, self-reported, and lack real-world insights into the daily burden of symptoms. They also rarely capture subtle shifts in patient quality of life. Our novel wearable, remote patient monitoring platform solves these challenges, providing objective 24/7 medical-grade measures of physiological and behavioral data from the comfort and convenience of a patient's home. Unlike other wearable technologies, we provide access to high-resolution, unfiltered, raw biosensor data that is crucial to develop high-quality digital biomarkers. Our high-fidelity data detects significant insights, even in small patient cohorts. Regeneron successfully used our platform as a Phase III exploratory endpoint in a Myasthenia Gravis clinical trial of 150 patients in 100+ countries. In MyoKardia's hypertrophic obstructive cardiomyopathy trial, we delivered an AI-based screening tool that achieved 95% accuracy, 95% sensitivity, and 95% specificity. Beyond pharma, we are expanding our library of digital biomarkers by partnering with academic medical centers. We are working with UCLA to develop objective measures for heart failure and also with Children's Hospital Los Angeles and USC to measure sickle cell pain.